Latest
Research, clinical trials, regulatory updates, and industry analysis from the longevity medicine world.
Aman Clinics has brought the Cenegenics longevity model to Doha. Here is what is confirmed, what remains unknown, and a buyer verification matrix.
David Sinclair's Lifespan.com combines longevity media, community, and research funding. Use this evidence scorecard before acting on any longevity claim.
A single FGF21 gene therapy dose improved healthspan and survival in aged mice. Here is the evidence, human translation path, and clinic red-flag guide.
Human Longevity now markets $599 whole-genome sequencing with AI interpretation. Compare what is included, what is uncertain, and eight questions to ask.
A new aging hypothesis and sex-specific biological age tests are reshaping women's longevity. Here is the WLC minimum standard for credible clinic care.
Tesamorelin has an FDA-approved HIV lipodystrophy indication, but not for longevity, ordinary weight loss, cognition, bodybuilding, or anti-aging.
A buyer guide to UFC GYM's PWR Clinics announcement, gym-based longevity medicine, and what to verify before buying GLP-1, TRT, peptide, IV, or recovery programs.
A buyer guide to longevity medicine implementation: how to judge clinic delivery, governance, AI claims, incidental findings, and follow-up before you pay.
Neko lists its UK scan at £299 and plans to open in New York on September 24, 2026, but no US price is public. Here is what the scan includes and what to verify.
A buyer guide to Human Longevity exam cost, HLI-style diagnostics, genetics, full-body imaging, and the follow-up questions to ask before paying.
A practical guide to the follow-up plan after a longevity assessment: clinical ownership, abnormal findings, referrals, retesting, records, costs, and red flags.
A buyer guide to longevity clinics in Canada, comparing membership medicine, assessment-led full-body MRI programs, and regenerative-care clinics.
A buyer scorecard for separating completed tests, biomarker changes, functional progress, patient-important outcomes, safety, and unresolved follow-up.
Retatrutide is promising in obesity trials, but products sold as retatrutide outside trials have triggered liver-toxicity warnings. Here is how clinic buyers can separate legitimate care from grey-market peptide risk.
The public follistatin and klotho study is a completed, industry-sponsored early-phase trial with 14 participants and no posted results. Here is what that means before paying for treatment.
A large Nature Medicine study inferred cell-type aging from plasma proteins. The model predicted risk at population level, but it is not a diagnosis or validated clinic treatment engine.
Focused ultrasound can temporarily open the blood-brain barrier in specialist Alzheimer's trials, but it is not routine longevity-clinic brain prevention.
ER-100 has entered a Phase 1 eye-disease trial. This is a safety milestone for partial epigenetic reprogramming, not approval or proof of whole-body age reversal.
Midjourney Medical's water-based ultrasonic scanner is a serious signal for longevity clinics, but the useful question is not hype. It is who interprets repeat imaging data, what changes in care, and who owns follow-up.
HUM2N at Six Senses London shows luxury hotels moving into clinic-like prevention. Here is how to judge whether hotel-based longevity clinics offer real medical workflow or spa branding.
Fountain Life does not show a standard membership price table. Here are the current official gift-card prices, what the tiers claim to include, and the written quote questions that make alternatives comparable.
A buyer-focused guide to epigenetic testing at longevity clinics: when biological-age clocks add useful context, when they become sales theater, and what to ask before paying.
A decision framework for choosing executive health, concierge prevention, or a longevity clinic in 2026 based on risk profile, diagnostics, follow-up, budget, and red flags.
A 2026 buyer guide to AI diagnostics in longevity clinics: real use cases, red flags, physician oversight, FDA caveats, and questions before you pay.
A regulation-first guide to choosing a longevity clinic in Dubai or Abu Dhabi by care model, evidence, licensing and follow-up.
Compare Swiss residential and outpatient longevity clinics by care model, evidence, regulation, follow-up and total itinerary rather than a universal ranking.
A Bangkok longevity-clinic due-diligence guide based on the one Thailand provider whose location WLC verified in this review, with a correction to Chi Longevity's location.
A cautious 2026 guide to cognitive decline, longevity clinics, brain-health tests, lifestyle evidence, referral pathways, and red flags.
DEXA scans can make longevity assessments more useful when clinics connect bone density, lean mass, and fat distribution to a real plan, not a vanity score.
A conservative 2026 guide to exosome therapy longevity clinic offers: evidence, FDA/EU regulation, costs, red flags, and safer alternatives.
A 2026 buyer guide to GLP-1s in longevity clinics: when they make medical sense, how to protect muscle, and which red flags to avoid.
A 2026 buyer guide to hormone optimization at longevity clinics: TRT, menopause therapy, thyroid/adrenal red flags, costs, monitoring, and questions.
A buyer guide to longevity blood panels: decision-relevant tests, selective add-ons, exploratory biomarkers, repeat-testing logic, and commercial red flags.
A patient-safety guide to longevity clinic governance: medical accountability, evidence labels, diagnostics, AI, biomarkers, records, adverse events, and conflicts.
A buyer guide to IV NAD+, IV NR, oral NR and NMN that separates biochemical effects from unproven longevity outcomes and checks sterile-compounding risks.
A source-verified USA longevity clinic shortlist comparing diagnostic assessments, memberships, hospital executive health, lab platforms, and MRI-only alternatives.
GLP-1 microdosing longevity clinics in 2026 need scrutiny: see evidence, healthy-lean caveats, product-quality risks, and buyer red flags.
IV nutrient therapy can be clinically useful for selected deficiencies, but anti-aging claims are weaker. Here is how to compare clinics, costs, and safety protocols.
Princeton Longevity Center does not publish one universal price. This guide documents current inclusions, quote requirements, insurance limits, electives, and follow-up questions.
VO2 max is one of the better-supported longevity metrics, but the value depends on testing quality, medical screening, and a plan after the number.
A decision guide to comparing 47 longevity clinics by care model, evidence, follow-up, regulation and fit, without treating one score as a universal winner.
There is no defensible average longevity-clinic price by country. Compare current official examples from Switzerland, Spain, Germany, the UK, the US, and Thailand, then normalize inclusions before booking.
Lepodisiran and muvalaplin lower Lp(a) in phase 2, but cardiovascular outcomes are not yet proven. Here is the current phase 3 status and the clinic workflow that matters now.
This weekly WLC intelligence digest covers serious clinic standards, AI diagnostics, GLP-1 programs, full-body MRI, biological-age testing, and peptides.
A buyer guide to longevity clinic data systems: wearables, dashboards, clinical records, AI, interoperability, privacy, escalation, and proof to request.
A dated May 2026 evidence check on five longevity-clinic trends: AI diagnostics, GLP-1s, biomarkers, imaging, and changing care models.
This week's radar covers blood-based Alzheimer's biomarkers, FDA-cleared imaging AI, DXA/DEXA upgrades, wearable VO₂ estimates, and smarter questions for buyers.
A practical 2026 guide to biological age testing in longevity clinics: epigenetic clocks, proteomic and multi-omics clocks, imaging-derived organ age, inflammatory markers, and the clinical tests that actually change decisions.
A clear 2026 guide to what longevity clinics do, what they cost, which tests matter, red flags to avoid, and how to compare clinics safely.
Longevity clinics are usually regulated through doctors, medicines, devices, diagnostics, premises, and advertising claims — not as one universal clinic category.
A source-verified guide to executive health costs in 2026, including published prices, quote-based programs, hidden follow-up costs, and questions to ask before paying.
A practical buyer’s guide to longevity health assessments: biomarkers, imaging, genetics, fitness testing, costs, and the questions to ask before booking.
A conflict-disclosed comparison of three Spanish longevity-clinic models using current provider pages, public price signals, clinical scope, evidence limits and booking questions.
A buyer's guide to full-body MRI at longevity clinics: what it can detect, what it misses, real cost models, false positives, and safer alternatives.
A provider-neutral 100-point scorecard for evaluating licensing, evidence, diagnostics, follow-up, pricing and records before paying a longevity clinic.
Compare longevity clinics in Switzerland, Spain, Germany, and the UK by licensing, care format, follow-up, travel risk, and evidence, not country stereotypes.
What the FDA's July meeting did and did not change for BPC-157, TB-500, MOTS-c, Semax, Epitalon and other peptides marketed by longevity clinics.
A late-life oxytocin and ALK5-inhibitor experiment extended remaining survival in male mice, but not females. Here is what the 73% result does and does not mean.
A cross-border guide to choosing European longevity clinics by care model, regulation, evidence and follow-up rather than static scores or universal winners.
NAD+ biology is relevant to brain aging research, but no human trial has shown that NAD+ therapy prevents, slows, or reverses Alzheimer's or Parkinson's disease.
A source-integrity correction separating Cleveland Clinic Florida's verified public health events and executive health service from an unverified longevity-event narrative.
A current status check of Clinique La Prairie AMAALA separating the announced 2027 opening, planned facilities and residences from prices, programs and booking details that remain unavailable.
What Lilly's Insilico agreement actually covers, why the $2.75B headline is contingent and why it does not create an approved longevity drug or a reason to buy clinic services today.
A live status check of Fountain Life's four listed locations, two coming-soon cities and the questions buyers should confirm before treating an announced center as operational.
A company announcement planned Niagen IV availability at more than 80 OneSpaWorld medi-spas. It confirms a commercial rollout, not clinical benefit, onboard availability, or superior safety.
Biological age tests can disagree because clocks use different targets, datasets, assays, and endpoints. This guide explains what accuracy means and what a result can actually change.
Buchinger Wilhelmi offers medically supervised fasting stays, while Chenot publishes a seven-night, 850-kcal program fee of CHF 5,500. Compare supervision, evidence limits, accommodation, and safety.
Clinique La Prairie publishes a CHF 31,800 seven-day Revitalisation package. Palazzo Fiuggi quotes most longevity programs individually. Compare scope and total cost without treating provider claims as outcomes.
A current, source-checked comparison of Fountain Life and Human Longevity covering public prices, diagnostics, locations, therapeutic claims and the questions to ask before paying.
The viral post verifies a clinic visit, not a protocol, price, result, or recommendation. This fact check separates the reported event from the medical claims added around it.
Lanserhof publishes seven-night packages with accommodation and a medical base program. SHA prices Advanced Longevity per night without accommodation. Here is how to normalize both quotes.
Cleveland Clinic publishes a detailed executive physical framework, while Mayo's official page could not be retrieved in this review. Compare written scope, insurance, follow-up, and total cost rather than guessed price bands.
A conflict-disclosed comparison of Progevita and Clinique La Prairie using current public prices, inclusions, evidence limits and a practical quote checklist.
WLC withdrew its Progevita-Lanserhof scores and recommendation because the methodology was not reproducible, source data had expired, and a claimed profile created an unresolved independence question.
Progevita and SHA sell different residential programs in Spain. This comparison uses current provider prices, separates accommodation from program fees, and discloses WLC's relationship with Progevita.
A buyer-focused review of senolytics in 2026: what human trials actually found, why dasatinib plus quercetin is not routine anti-aging care, and what to verify before considering a clinic protocol.
WLC withdrew its 2026 peptide-clinic ranking because provider flags, marketing sources, dose tables, prices, and a claimed FDA reclassification did not support a safe recommendation.
An HHS announcement prompted reports of a peptide reclassification. Later FDA records show why an announcement, compounding policy, drug approval, and clinical evidence are different questions.
A 2025 Aging editorial offers a useful agenda for longevity clinics, but it is a three-page, one-author opinion with one reference, not an evidence review or consensus statement.
ARPA-H's PROSPR program funds seven teams with up to $144 million. Here is what the program is testing, what its milestones mean, and why it is not yet validation of a healthspan treatment.
WLC withdrew its 2026 stem-cell clinic ranking because the evidence did not support recommendations, prices, candidate profiles, or maintenance schedules. Here is what patients can verify instead.
A destination longevity program is still health care abroad. Use this CDC-based checklist to assess the clinic, clinician, procedure, travel risks, records, insurance, and follow-up before paying.
HLI and LEV announced multi-omic research using centenarian blood samples. The release confirms the partnership and methods, but omits sample size, endpoints, timeline, and a public protocol.
A current provider map shows three different Southern California models: scan-focused imaging, primary and concierge care, and integrated genomic assessment. They should not be compared as one product.
Longevity Clinics World can help build a shortlist, but a directory listing is not accreditation. Use these checks for credentials, evidence, total cost, follow-up, and conflicts.
A reassessment of 2025 longevity milestones by evidence type: investment, infrastructure, research frameworks, competitions, and the clinical conclusions none of them support yet.
A Cell Stem Cell paper restored function in aged mouse blood stem cells by modulating lysosomes ex vivo. It is a mechanism study, not a human anti-aging treatment.
Therapeutic plasma exchange is established for selected diseases, not for extending healthy lifespan. A 42-person trial changed epigenetic clocks, but did not test fewer diseases, better function, or longer life.
UT Health San Antonio described a multi-phase rapamycin project and a separate short recruitment study. Here is what each protocol tests, what remains unknown, and what the announcement does not prove.
US longevity clinics are not outside regulation, but oversight is split. This map explains FDA product rules, state professional oversight, compounding, off-label care, and what patients can verify.
ArentFox Schiff's longevity practice announcement is a useful prompt for an operator checklist covering licensing, claims, products, data, contracts, and cross-border care.
BBC reporting shows a market ranging from ordinary prevention to expensive tests and experimental treatments. This guide separates documented offers from proven health benefit.
A current comparison of Biograph Core and Black: price, tests, clinical touchpoints, exclusions, and the questions to ask before paying for a diagnostic membership.
The Cleveland Clinic and PGA TOUR partnership runs through 2032. This fact check separates the traveling clinical services and planned 2027 center from unreported outcomes.
Cash payment is not itself a warning sign, but selling tests or products can create conflicts. Use this evidence contract to separate the medical fee, product revenue, claims, and follow-up.
LifeWellMD advertises TRT, exosomes, peptides, infusions, and biological-age protocols. This claim audit shows what its own site establishes and what FDA or clinical guidance requires.
Longevity Docs promotes evidence, supervision, and traceable peptide supply. FDA records show why patients and clinics must verify the ingredient, compounder, lot, and regulatory pathway.
A clinic's use of the words stem cell or regenerative does not reveal its legal pathway. This guide explains EU ATMP classification, central authorisation, trials, the hospital exemption, and warning signs.
The Nature Metabolism review found sparse human tissue data and limited clinical efficacy. Three 2026 studies add narrow signals, but do not establish NAD+ interventions as general longevity treatments.
The Atlantic raises valid questions about screening, peptides, off-label drugs, and compounded products. We checked those points against FDA and radiology guidance.
The brand lists 16 planned centers across 10 US states, but every location is still marked Coming Soon. Here is what is public, what remains unverified, and what patients should ask before booking.
